A Phase 1 interventional study of Belumosudil and Itraconazole in Drug-drug Interaction, Autoimmune Diseases and Fibrotic Disease, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 40th largest by enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 1, and was the 30th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 18+
Purespring Therapeutics Limited · Sites in United Kingdom, United States
Ages 18+
Imagine Institute · Sites in United Kingdom, Austria, Belgium and 8 more countries
Takeda · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18+
Immunovant Sciences GmbH · Sites in United Kingdom, United States, Argentina and 12 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 19 · Phase 3 24 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 94 across the 65 interventional studies, 2,424 across the 8 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 4 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Autoimmune Diseases with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
| NCT06193889Phase 3Kyverna TherapeuticsKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | 2027-09 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.
Part 1:
The primary objective of Part 1 of this study is to determine the effect of itraconazole, rifampicin, and rabeprazole on the pharmacokinetics of once daily (QD) orally administered belumosudil in healthy male subjects. Part 1 consists of 4 periods.
In each study period, subjects will receive a single dose of belumosudil, in the fed state. Additionally, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of perpetrator drugs in Periods 2 to 4; a strong CYP3A4 inhibitor, itraconazole, in Period 2; a proton pump inhibitor, rabeprazole, in Period 3; and a strong CYP3A4 inducer, rifampicin, in Period 4.
Subjects will receive a total of 4 single oral dosses of investigative product (IP), 200 mg belumosudil QD, in the fed state over 4 periods (each lasting 3 days with a minimum washout of 2, 8, and 4 days following completion of Periods 1, 2, and 3, respectively). Subjects also will receive 9 single oral doses of itraconazole 200 mg (QD over 9 days) in Period 2; 7 single oral doses of rabeprazole 20 mg (BID over 3 days followed by QD on 1 day) in Period 3; and 9 single doses of rifampicin 600 mg (QD over 9 days) in Period 4.
A follow-up visit will take place 3 to 5 days post-final discharge.
Part 2:
The primary objective of Part 2 of this study is to determine the effect of omeprazole on the PK of a single-day twice daily (BID; every 12 hours [Q12h]) dose of belumosudil administered orally, in healthy male subjects. Part 2 consists of 2 periods.
In Period 1, subjects will receive a single dose of belumosudil, in the fed state. In Period 2, in order to assess the effects of inhibition and induction of CYP3A4 and the elevation of gastric pH on belumosudil exposure, subjects will receive multiple doses of a proton pump inhibitor, omeprazole.
Subjects will receive a total of 4 single oral doses of IP (200 mg belumosudil, BID [Q12h] on 2 occasions) in the fed state over 2 periods (each lasting 3 days with a minimum washout of 2 days between dosing in Period 1 and the start of dosing with non-IP in Period 2). Subjects will also receive 4 single oral doses of omeprazole 20 mg (QD over 4 days) in Period 2.
A follow-up visit will take place 3 to 5 days post-final discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has a history or presence of any of the following:
Subjects Agreed to the Following Restrictions During the Duration of the Study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
Drug: Belumosudil
Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7. Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9
Drug: Belumosudil · Drug: Itraconazole
Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3. Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4.
Drug: Belumosudil · Drug: Rabeprazole
Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9. Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10.
Drug: Belumosudil · Drug: Rifampicin
Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
Drug: Belumosudil
Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3. Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4.
Drug: Belumosudil · Drug: Omeprazole
Development candidate
Also known as: Rezurock, SLx-2119
Perpetrator drug
Perpetrator drug
Perpetrator drug
Perpetrator drug
Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1
Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose
Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose
Pharmacokinetics: Cmax of KD025m1 in Part 1
Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose
Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose
Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2
Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose
Time frame: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose
Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2
Area under concentration-time curve from zero hours to infinity (AUC\[0-inf\]) and from zero hours to 24 hours post-dose (AUC\[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2
Time frame: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22,24,36, and 48 hours post-dose
Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2
Area under concentration-time curve from zero hours to 24 hours post-dose (AUC\[0-24\]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2
Time frame: Part 1: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12, and 24 hours post-dose; Part 2: Pre-dose and 0.5,1,1.5,2,3,4,5,6,8,10,12,12.5,13,13.5,14,15,16,17,18,20,22, and 24 hours post-dose
This was a single centre, non-randomised, open label, two-part study. Part 1 of the study was a 4-period sequential dose study in healthy male subjects. The estimated duration from screening to discharge from the study was approximately 10 weeks. Part 2 of the study was a 2-period sequential dose study in healthy males. The estimated duration from screening to discharge from the study was approximately 7 weeks.
| Milestone | Part 1 Belumosudil (KD025) QD Dosing | Part 2 Belumosudil (KD025) BID Dosing |
|---|---|---|
| Started | 35 | 38 |
| Completed | 35 | 38 |
| Not completed | 0 | 0 |
| Milestone | Part 1 Belumosudil (KD025) QD Dosing | Part 2 Belumosudil (KD025) BID Dosing |
|---|---|---|
| Started | 35 | 38 |
| Completed | 35 | 38 |
| Not completed | 0 | 0 |
| Milestone | Part 1 Belumosudil (KD025) QD Dosing | Part 2 Belumosudil (KD025) BID Dosing |
|---|---|---|
| Started | 35 | 0 |
| Completed | 32 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | Part 1 Belumosudil (KD025) QD Dosing | Part 2 Belumosudil (KD025) BID Dosing |
|---|---|---|
| Started | 32 | 0 |
| Completed | 30 | 0 |
| Not completed | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Maximum concentration (Cmax) of the parent drug, KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2) for belumosudil alone, belumosudil + itraconazole, belumosudil + rabeprazole, and belumosudil + rifampicin at 0 to 48 hours post-dose
| ng/mL | Part 1, Period 1: Belumosudil Alone | Part 1, Period 2: Belumosudil + Itraconazole | Part 1, Period 3: Belumosudil + Rabeprazole | Part 1, Period 4: Belumosudil + Rifampicin |
|---|---|---|---|---|
| Parent Drug KD025 | 1770 ± 31.3 | 2130 ± 31.0 | 227 ± 58.4 | 712 ± 35 |
| KD025m2 | 337 ± 54.7 | 221 ± 60.8 | 23.5 ± 70.7 | 148 ± 57.3 |
Maximum concentration (Cmax) of Metabolite 1 (KD025m1) for belumosudil alone and for belumosudil + rifampicin up to 48 hours post-dose
| ng/mL | Part 1, Period 1: Belumosudil Alone | Part 1, Period 4: Belumosudil + Rifampicin |
|---|---|---|
| Pharmacokinetics: Cmax of KD025m1 in Part 1 | 23.2 ± 40.0 | 52.5 ± 34.0 |
Maximum concentration (Cmax) of the parent drug (KD025), for Metabolite 1 (KD025m1), and for Metabolite 2 (KD025m2), for belumosudil alone and for belumosudil + omeprazole up to 48 hours post-dose
| ng/mL | Part 2, Period 1: Belumosudil Alone | Part 2, Period 2: Belumosudil + Omeprazole |
|---|---|---|
| Cmax--1st dose: KD025 | 1790 ± 34.5 | 575 ± 145.7 |
| Cmax--2nd dose: KD025 | 1760 ± 37.0 | 903 ± 63.8 |
| Cmax--1st Dose: KD025m1 | 23.8 ± 39.6 | 18.0 ± 54.6 |
| Cmax--2nd Dose: KD025m1 | 23.6 ± 46.4 | 18.9 ± 48.7 |
| Cmax--1st Dose: KD025m2 | 282 ± 75.6 | 72.3 ± 166.8 |
| Cmax--2nd Dose: KD025m2 | 257 ± 83.9 | 115 ± 121.8 |
Area under concentration-time curve from zero hours to infinity (AUC\[0-inf\]) and from zero hours to 24 hours post-dose (AUC\[0-24)) for the parent drug KD025, and Metabolite 2, KD025m2, for subjects up to 48 hours each for Part 1 and for Part 2
| (ng*h)/mL | Part 1, Period 1: Belumosudil Alone | Part 1, Period 2: Belumosudil + Itraconazole | Part 1, Period 3: Belumosudil + Rabeprazole | Part 1, Period 4: Belumosudil + Rifampicin | Part 2, Period 1: Belumosudil Only | Part 2, Period 2: Belumosudil + Omeprazole |
|---|---|---|---|---|---|---|
| AUC(0-inf): KD025 | 9080 ± 33.3 | 11200 ± 38.1 | 1680 ± 65.8 | 2500 ± 34.5 | 18800 ± 37.1 | 9880 ± 59.2 |
| AUC(0-inf): KD025m2 | 1230 ± 69.5 | 843 ± 73.7 | 174 ± 11.1 | 396 ± 50.2 | 1900 ± 90.4 | 1110 ± 30.3 |
| AUC(0-24): KD025 | 8430 ± 30.5 | 10400 ± 35.8 | 1510 ± 60.7 | 2490 ± 34.1 | 16800 ± 36.4 | 7970 ± 58.9 |
| AUC(0-24): KD025m2 | 1100 ± 63.7 | 745 ± 70.7 | 110 ± 84.0 | 376 ± 56.7 | 1950 ± 82.3 | 767 ± 115.3 |
Area under concentration-time curve from zero hours to 24 hours post-dose (AUC\[0-24\]) for Metabolite 1, KD025m1, for subjects in Part 1 and for subjects in Part 2
| (ng*h)/mL | Part 1, Period 1: Belumosudil Alone | Part 1, Period 4: Belumosudil + Rifampicin | Part 2, Period 1: Belumosudil Alone | Part 2, Period 2: Belumosudil + Omeprazole |
|---|---|---|---|---|
| Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2 | 75.6 ± 42.1 | 148 ± 41.9 | 138 ± 91.3 | 91.5 ± 76.3 |
Collected over Part 1, Period 1: 1 day Part 1, Period 2: 9 days Part 1, Period 3: 4 days Part 1, Period 4: 10 days Part 2, Period 1: 1 day Part 2, Period 2: 4 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1, Period 1: Belumosudil Only | 0/35 (0%) | 0/35 (0%) | 6/35 (17.1%) |
| Part 1, Period 2: Belumosudil + Itraconazole | 0/35 (0%) | 1/35 (2.9%) | 9/35 (25.7%) |
| Part 1, Period 3: Belumosudil +Rabeprazole | 0/33 (0%) | 0/33 (0%) | 6/33 (18.2%) |
| Part 1, Period 4: Belumosudil + Rifampicin | 0/32 (0%) | 0/32 (0%) | 8/32 (25%) |
| Part 2, Period 1: Belumosudil Only | 0/38 (0%) | 0/38 (0%) | 9/38 (23.7%) |
| Part 2, Period 2: Belumosudil + Omeprazole | 0/38 (0%) | 0/38 (0%) | 5/38 (13.2%) |
| Event | Part 1, Period 1: Belumosudil Only | Part 1, Period 2: Belumosudil + Itraconazole | Part 1, Period 3: Belumosudil +Rabeprazole | Part 1, Period 4: Belumosudil + Rifampicin | Part 2, Period 1: Belumosudil Only | Part 2, Period 2: Belumosudil + Omeprazole |
|---|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/35 | 1/35 | 0/33 | 0/32 | 0/38 | 0/38 |
| Event | Part 1, Period 1: Belumosudil Only | Part 1, Period 2: Belumosudil + Itraconazole | Part 1, Period 3: Belumosudil +Rabeprazole | Part 1, Period 4: Belumosudil + Rifampicin | Part 2, Period 1: Belumosudil Only | Part 2, Period 2: Belumosudil + Omeprazole |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/35 | 1/35 | 1/33 | 3/32 | 6/38 | 1/38 |
| Abdominal distensionGastrointestinal disorders | 3/35 | 0/35 | 0/33 | 0/32 | 0/38 | 0/38 |
| NasopharyngitisInfections and infestations | 0/35 | 0/35 | 0/33 | 0/32 | 0/38 | 3/38 |
| SomnolenceNervous system disorders | 0/35 | 2/35 | 0/33 | 1/32 | 0/38 | 0/38 |
| Back painMusculoskeletal and connective tissue disorders | 0/35 | 2/35 | 0/33 | 0/32 | 0/38 | 0/38 |
| FatigueGeneral disorders | 0/35 | 0/35 | 1/33 | 1/32 | 0/38 | 0/38 |
| Back injuryInjury, poisoning and procedural complications | 0/35 | 0/35 | 0/33 | 1/32 | 0/38 | 0/38 |
| LacerationInjury, poisoning and procedural complications | 0/35 | 0/35 | 0/33 | 1/32 | 0/38 | 0/38 |
| Seasonal allergyImmune system disorders | 0/35 | 1/35 | 0/33 | 1/32 | 0/38 | 0/38 |
| NeutropeniaBlood and lymphatic system disorders | 0/35 | 0/35 | 0/33 | 1/32 | 0/38 | 0/38 |
| Age, Continuous(years) | All Subjects Part 1: KD025 QD Dosing | All Subjects in Part 2: KD025 BID Dosing | Total |
|---|---|---|---|
| Mean | 37.0 ± 11.8 | 32.6 ± 10.6 | 34.7 ± 11.4 |
| Sex: Female, Male(Participants) | All Subjects Part 1: KD025 QD Dosing | All Subjects in Part 2: KD025 BID Dosing | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 35 | 38 | 73 |
| Race (NIH/OMB)(Participants) | All Subjects Part 1: KD025 QD Dosing | All Subjects in Part 2: KD025 BID Dosing | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 |
| White | 28 | 35 | 63 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| BMI (body mass index)(kg/m^2) | All Subjects Part 1: KD025 QD Dosing | All Subjects in Part 2: KD025 BID Dosing | Total |
|---|---|---|---|
| Mean | 26.81 ± 3.00 | 25.94 ± 3.36 | 26.36 ± 3.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Feb 2019, 9 months.
Results were first posted in Sep 2021, 2 years 7 months after primary completion.
Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 9 months is below that.
Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil